Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
| Autor: | M. Gamil, Ann Vandevoorde, Veerle Van Eygen, Pieter Van Remoortere, Fred Poordad, Donghan Luo, Eric Lawitz, Julio A. Gutierrez, Greet Beets, Leen Vijgen, Maria Beumont |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Simeprevir
medicine.medical_specialty Daclatasvir Sofosbuvir Hepatitis C virus simeprevir medicine.disease_cause Gastroenterology sofosbuvir Liver disease Internal medicine medicine Decompensation Research Articles decompensation business.industry FibroTest Gastroenterology/Hepatology portal hypertension General Medicine Hepatitis C medicine.disease Infectious Diseases Medicine hepatitis C business medicine.drug Research Article |
| Zdroj: | Health Science Reports Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020) |
| ISSN: | 2398-8835 |
| Popis: | Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhotic patients typically require a longer treatment duration and less is known regarding the long‐term durability of SVR or effect on liver disease progression; to assess this, the IMPACT study followed patients for a 3‐year period after end of treatment. Methods The Phase II, open‐label, nonrandomized IMPACT study assessed the efficacy, safety, and pharmacokinetics of the combination of three DAAs (simeprevir, sofosbuvir, and daclatasvir) in HCV genotype 1/4‐infected, treatment‐naïve/‐experienced cirrhotic patients with portal hypertension or decompensated liver disease. Patients from a single site in the United States were assigned to one of two groups by Child–Pugh (CP) score: CP A, CP score less than 7 and evidence of portal hypertension; CP B, CP score of 7 to 9. All patients received simeprevir 150 mg, daclatasvir 60 mg, and sofosbuvir 400 mg once‐daily for 12 weeks between September 2014 and August 2015. All 40 patients included in the study (male, 63%; median age, 58.5 years) achieved SVR 12 and 24 weeks after end of treatment, and the combination was well tolerated. Results All patients who reached the 3‐year follow‐up timepoint maintained SVR (CP A, 15/15; CP B, 18/18). CP scores and Model for End‐stage Liver Disease scores remained relatively stable, and mean FibroScan and FibroTest scores declined. No new safety signals were identified. Conclusions In the IMPACT study, virologic response to simeprevir, sofosbuvir, and daclatasvir was durable over 3 years (http://ClinicalTrials.gov number: NCT02262728). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text